I'm glad I went along today. It appeared to be a larger turnout than expected, as the back of the room was very crowded with people standing. Virtually the whole Paradigm team was there, and a few "VIPs" such as Diesel Williams, former Carlton AFL player Simon White (who uses the drug), and Mitch someone, former NFL player possibly with the PPEN? He has apparently been helping Dr Michels to recruit the 10 NFL players (all of whom have been recruited now).
Anyway, Paul Rennie went through the presentation at the top of this thread. It's always compelling when you go to an AGM as that's what the preso is designed to be - but there was definitely a bit of bubble in the room. I've seen less happy AGMs, put it like that. PR even cracked a joke or two as he went through. Nothing of great note that we haven't seen before.
They fielded a couple of questions at the end. From memory, one was about potential rival treatments such as the stem-cells, PRPs etc and was answered by the point that none have achieved Phase 2B success yet. Another question was on the timings associated with Phase III, which is to being in 2020, and Paul Rennie said that they'd probably aim for a 56 day trial (6 week treatment, and then 2 weeks monitoring afterwards), and confirmed that pain would be primary endpoint (rather than BMEL depletion, an idea which I think was floated on this forum a while back). However, on the timeframe, Paul emphasised that it may be longer, and they would be guided by the FDA on that. They may seek to increase the numbers in the Phase III trial to 600. There was also a question on Big Pharma interest, and Paul batted away speculation that the last CR occurred because interest was not at the level/value the board would have liked. They have ongoing interest from pharma companies who are largely very impressed with the Phase 2B data. They are having a board meeting next week where they will seek to characterise the type of partner and partnership that the company would prefer, and I got the distinct impression that a) they'd prefer partnering to any takeover, and b) if/when a partner is selected it will be about much more than who is offering the best financial deal.
It should perhaps be added that Paul also at one point addressed formally that the reason there was one tweet and one tweet only from Dr Michels, was because the IRB didn't want commentary and he was asked not to tweet anymore. No conspiracies, no disasters. The product was fine and ready to go, but could not be sent until after the IRB ticked everything off. Highly regulated industry, as it should be.
Anyway, I think that's all from the top of my head. Oh wait, I know it's froth and doesn't guarantee anything, but Paul was confident enough to end his presentation by saying that the last 12 months have been great for the company, but that "you ain't seen nothing yet". Whilst that probably akin to Mozzarc posting a rocket ship on HC
I thought i'd add it in to highlight the comfortable and confident mood of the CEO.
(20min delay)